Mindbio Therapeutics Nominated for Company of the Year in Industry Awards

VANCOUVER, BC / ACCESSWIRE / October 26, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to report the Company has been nominated for Company of the Year as well as other profile awards, at the upcoming industry awards (Wonderland, presented by Microdose) to be held in Miami in November. Last year, MindBio and its Chief Executive Officer, Justin Hanka won a number of awards including Company of the Year, Entrepreneur of the Year, Innovator of the Year and LSD Company of the Year.

You can vote once per day until Friday 3 November 2023. We encourage our supporters and shareholders to participate by voting in the link here:

VOTE HERE

https://awards.wonderlandconference.com/vote/

MindBio and it's Chief Executive Officer, Justin Hanka in this year's industry awards have been nominated in the following categories:

• Company of the Year - MindBio Therapeutics
• B2B Tech Company of the Year - MindBio Therapeutics
• B2C Tech Company of the Year - MindBio Therapeutics
• Innovator of the Year - Justin Hanka
• Hero of the Year - Justin Hanka

Dr Suresh Muthukumaraswamy, MindBio's lead scientific investigator conducting the LSD-Microdosing clinical trials in collaboration with MindBio has also deservedly been nominated for Academic of the Year and the University of Auckland in New Zealand, where Suresh is an Associate Professor, has been nominated for University of the Year. We would be delighted if you would support our terrific team and esteemed academic colleagues by voting in all categories.

The nominations are welcomed by the MindBio team at a time where MindBio's proprietary drug MB22001, a titratable form of LSD for take-home microdosing is progressing well through Phase 2a clinical trials in patients with Major Depressive Disorder.

Microdose operate one of the largest events in the psychedelics industry every year, Wonderland, a coming together of industry leaders and educators inspiring a new generation of practitioners in the wellness industry.

We invite you to join us in support of creating a brighter future for mental health.

VOTE HERE: https://awards.wonderlandconference.com/vote/

Receive our latest updates here: https://www.mindbiotherapeutics.com/get-updates

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true

Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/

For further information, please contact:

Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com

About MindBio Therapeutics

MindBio is a biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home LSD-Microdosing human clinical trials. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials microdosing Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2 clinical trial in development microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial in development microdosing LSD in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

Cautionary Note Concerning Forward-Looking Statements:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: MindBio Therapeutics